Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott troponin test shows benefits in diagnosing heart attacks

Abbott troponin test shows benefits in diagnosing heart attacks

5th September 2013

Abbott has announced preliminary results from a new study that underlines the significant benefits offered by its Architect Stat High Sensitive Troponin-I test.

Data from the trial – which is being carried out by the University of Edinburgh – showed that the test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack.

It functions by measuring levels of cardiac troponin, a protein found in the heart muscle associated with injuries, which is considered the preferred biomarker to identify suspected heart attacks.

Since it can measure low levels of this protein, Abbott's test offers particular benefits in the diagnosis of female patients, who have lower peak levels of troponin than men and are therefore frequently underdiagnosed.

Dr John Frels, divisional vice-president for diagnostics research at Abbott, said: "This is the first time we have seen a test that can provide this kind of detailed information to doctors and has the potential to aid doctors with improving the odds of survival."

This comes after the firm shared data from a separate trial of the assay conducted at the Brigham and Women's Hospital last month, which demonstrated the advantages it can provide compared to currently-available products.ADNFCR-8000103-ID-801634300-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.